Last reviewed · How we verify
xisomab 3G3- Dose 1
At a glance
| Generic name | xisomab 3G3- Dose 1 |
|---|---|
| Also known as | AB023- Dose 1, AB023- Dose 2, AB023- Dose 3, AB023- Dose 4 |
| Sponsor | Aronora, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis (PHASE2)
- Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- xisomab 3G3- Dose 1 CI brief — competitive landscape report
- xisomab 3G3- Dose 1 updates RSS · CI watch RSS
- Aronora, Inc. portfolio CI